ACTRN12609000086268招募中1 期
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of KDF-07002 in Healthy, Adult Volunteers
ucleus Network, Ltd.0 个研究点目标入组 54 人开始时间: 2009年2月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Diagnosis
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years(—)
- 性别
- Male
入选标准
- •1. Be a male between the ages of 18 and 60 years, inclusive.
- •2. Be healthy and have an acceptable medical history (defined as individuals who in the view of the investigator are free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, infective, or psychiatric diseases and confirmed by medical history, physical examination, and laboratory tests).
- •3. Have readily accessible peripheral venous access sites for administration of clinical trial material and blood sampling.
- •4. Subjects who are sexually active must also agree to a reliable form of contraception during the study and for 30 days following administration of the study drug.
- •5. Have the ability to understand the requirements of the study, be willing to provide written informed consent as evidenced by signature on an informed consent document approved by the institution’s Human Research Ethics Committee (HREC), and agree to abide by the study restrictions
排除标准
- •1. Have a known sensitivity to any imaging contrast agents
- •2. Be an intravenous drug user, user of any illicit drugs, or dependent on alcohol
- •3. Have participated in an investigational drug or device study within the past 30 days
- •4. Have donated blood or blood products within the past 30 days prior to pretreatment baseline
- •5. Have had surgery or suffered injury involving significant blood loss within the past 45 days
- •prior to pretreatment baseline period.
- •6. Have any clinically significant abnormal laboratory test based on clinical chemistry, hepatic
- •profile, renal profile, hematology, or coagulation measures
- •7. Have epilepsy or a history of grand mal seizure
- •8. Have a red blood cell disorder such as hemoglobinopathies or anemia
- •9. Have asthma, Chronic Obstructive Pulmonary Disease, Restrictive Pulmonary Disease or any
- •other allergic respiratory diseases
- •10. Have hepatic disease (liver function tests greater than 1.5 times the upper limit of normal)
- •11. Have renal impairment with serum creatinine > 105 mmol/L and/or Glomerular Filtration Rate (GFR) <60 mL/min.
- •12. Have splenic disorders such as hepatosplenomegally, splenomegally or splenectomy
- •13. Have a history of pancreatitis
- •14. Have thrombocytopenia (<150,000 platelets/mm3)
- •15. Have a blood-clotting disease including hemophilia or von Willebrand disease
- •16. Be currently taking warfarin (Coumadin®)
- •17. Have a known allergy to eggs
研究者
相似试验
撤回
1 期
A Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AD-6626 in Normal, Healthy VolunteersThis study is for healthy volunteers. The intended use of the investigational product is the treatment of Fanconi AnemiaBlood - Haematological diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12615000601538Aldea Pharmaceuticals24
已完成
1 期
A Single-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of Various Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia.Skin - Dermatological conditionsAndrogenetic AlopeciaACTRN12613000974707Samumed LLC30
已完成
1 期
A Single-Center, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045 Administered Orally to Normal, Healthy VolunteersPeripheral arterial diseaseACTRN12618000195257Foresee Pharmaceuticals Co., Ltd.24
未知
1 期
Multiple-Dose Phase 1 Study of SCO-792JPRN-jRCT2080223770SCOHIA PHARMA, Inc.36
未知
1 期
Single-Dose Phase 1 Study of TAK-792Healthy Adult Male ParticipantsJPRN-jRCT2080222845TAKEDA PHARMACEUTICAL COMPANY LTD.103
